Fig. 4

a Pain Intensity: T-scores (with 95% CIs) for PROMIS-43 and BPI subdomains of pain intensity—comparison between Baseline, Week 2, and Week 4 measurements. Dose −: (N = 16) dose decreased at Week 2 study visit; Dose + : (N = 28) dose increased at Week 2 study visit. b Pain Interference: T-scores (with 95% CIs) for PROMIS-43 and BPI subdomains of pain interference (BPI multiplied by 10 for scaling)—comparison between Baseline, Week 2, and Week 4 measurements. Dose –: (N = 16) dose decreased at Week 2 study visit; Dose + : (N = 28) dose increased at Week 2 study visit